Reijing Biotechnology established an AI pharmaceutical company to accelerate the research and development of small nucleic acid drugs.

According to Rejing Biology, recently, Rejing Biology officially registered and established Beijing Shangjing Intelligent Drug Technology Co., Ltd., marking the completion of a phased landing of the company's AI drug development strategy starting in 2023. The company will continue to increase investment in AI technology in the field of innovative drug business, especially in restructuring the research and development paradigm of small nucleic acid drugs with AI technology, accelerating the intelligent upgrade of the company's small nucleic acid drug pipeline.